Mast Cell Stabilizers for Fever and Hypercytokinemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercytokinemia, such as those induced by influenza infections, fail to effectively address the overly robust immune response, leading to severe inflammation and tissue damage, as they either downregulate the immune system too much or focus solely on neutralizing the pathogen without managing the cytokine storm.
Innovation Solution
Administering a mast cell stabilizing compound, like ketotifen or norketotifen, to reduce the release of inflammatory mediators, combined with an antiviral agent to target the infection, thereby balancing the immune response and allowing the adaptive immune system to clear the pathogen while controlling hypercytokinemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current treatments downregulate the immune system to reduce inflammation, then inflammatory response is reduced, but pathogen clearance capability is compromised
Solution Approach 1:
The treatment approach segments the immune response into two distinct components: mast cell-mediated inflammatory response (targeted for suppression) and adaptive immune response (preserved for pathogen clearance). This is achieved by selectively targeting mast cells with specific stabilizing compounds while leaving other immune mechanisms intact.
Solution Approach 2:
Mast cell stabilizing compounds act as intermediaries that selectively modulate mast cell degranulation and mediator release without broadly suppressing the entire immune system. These compounds serve as the mediating agent between the pathogen presence and the immune response, allowing controlled reduction of harmful inflammation while preserving protective immunity.
2Quantity of substance
If current treatments focus solely on neutralizing the pathogen, then pathogen load is reduced, but hypercytokinemia and tissue damage worsen
Solution Approach 1:
The treatment applies preliminary action by stabilizing mast cells before they can degranulate and release excessive inflammatory mediators in response to pathogen detection. This preventive approach blocks the cascade that would otherwise lead to hypercytokinemia, addressing the harmful response before it fully develops.
Solution Approach 2:
The treatment converts the potentially harmful mast cell response into a beneficial controlled response. By stabilizing mast cells, the therapy harnesses their pathogen-detecting capability while preventing their harmful degranulation, transforming what would be a source of hypercytokinemia into a controlled protective mechanism.
3Object-affected harmful factors
If mast cell stabilizing compounds are used to control inflammatory mediators, then hypercytokinemia is reduced, but immune response monitoring becomes more complex
Solution Approach 1:
Mast cell stabilizing compounds provide multi-functionality by simultaneously addressing multiple aspects of the immune response: they reduce inflammatory mediator release, control cytokine production, and prevent tissue damage, all through a single mechanism of mast cell stabilization. This consolidates multiple therapeutic effects into one intervention.
Data Source
AI summary
The present invention relates to methods for treating fever using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.